Literature DB >> 11347762

The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.

T Baba, K Shimada, S Neugebauer, D Yamada, S Hashimoto, T Watanabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11347762     DOI： 10.2337/diacare.24.5.953

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  15 in total

1.  Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.

Authors:  Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay
Journal:  Pancreas       Date:  2015-05       Impact factor: 3.327

2.  Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione.

Authors:  M Emoto; N Fukuda; Y Nakamori; A Taguchi; S Okuya; Y Oka; Y Tanizawa
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

3.  The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

Authors:  J E Tooke; L M Elston; K M Gooding; C I Ball; D M Mawson; J Piper; R Sriraman; R Urquhart; A C Shore
Journal:  Diabetologia       Date:  2006-03-01       Impact factor: 10.122

Review 4.  Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

Authors:  André J Scheen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Authors:  Michaela Diamant; Robert J Heine
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.

Authors:  Akiko Higuchi; Koji Ohashi; Rei Shibata; Saki Sono-Romanelli; Kenneth Walsh; Noriyuki Ouchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-12       Impact factor: 8.311

Review 7.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

8.  Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside.

Authors:  Angélica Amorim Amato; Francisco de Assis Rocha Neves
Journal:  PPAR Res       Date:  2012-06-14       Impact factor: 4.964

9.  Correlation between changes in blood pressure with insulin resistance in type 2 diabetes mellitus with four weeks of pioglitazone therapy.

Authors:  Sandip Kumar Dash
Journal:  Int J Diabetes Dev Ctries       Date:  2008-10

10.  VEGFB/VEGFR1-Induced Expansion of Adipose Vasculature Counteracts Obesity and Related Metabolic Complications.

Authors:  Marius R Robciuc; Riikka Kivelä; Ian M Williams; Jan Freark de Boer; Theo H van Dijk; Harri Elamaa; Feven Tigistu-Sahle; Dmitry Molotkov; Veli-Matti Leppänen; Reijo Käkelä; Lauri Eklund; David H Wasserman; Albert K Groen; Kari Alitalo
Journal:  Cell Metab       Date:  2016-04-12       Impact factor: 27.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.